Fluclotizolam
Fluclotizolam is a thienotriazolodiazepine derivative which was first synthesised in 1979,[1] but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified in 2017.[2][3][4]
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C15H10ClFN4S |
| Molar mass | 332.78 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
References
- US 4155913, Hellerbach J, Zeller P, Binder D, Hromatka O, "Thienotriazolodiazepine derivatives.", issued 22 May 1979, assigned to Hoffmann La Roche Inc
- Zawilska JB, Wojcieszak J (July 2019). "An expanding world of new psychoactive substances-designer benzodiazepines". Neurotoxicology. 73: 8–16. doi:10.1016/j.neuro.2019.02.015. PMID 30802466.
- Moosmann B, Auwärter V (2018). "Designer Benzodiazepines: Another Class of New Psychoactive Substances.". In Maurer H, Brandt S (eds.). New Psychoactive Substances. Handbook of Experimental Pharmacology. Handbook of Experimental Pharmacology. 252. pp. 383–410. doi:10.1007/164_2018_154. ISBN 978-3-030-10560-0. PMID 30367253.
- Chetraru E, Ameline A, Gheddar L, Raul JS, Kintz P (February 2018). "Les designer benzodiazepines: qu'en sait-on aujourd'hui?". Toxicologie Analytique et Clinique. 30 (1): 5–18. doi:10.1016/j.toxac.2017.12.001.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.